The headline reads as positive (93% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › EHC
Encompass Health Corp (EHC) stock analysis
BUY 42% confidence · analysed Oct 29, 2026
On Oct 29, 2026, our model rated Encompass Health Corp (EHC) BUY with 42% confidence at a price of $122.09. That means most of the technical, fundamental, money-flow and news signals point to upside.
Analysed price$122.09
Technical picture
The 14-day RSI is 49, close to the neutral 50 line, so momentum is balanced.
MACD is below its signal line, so short-term momentum is pointing down.
The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.
Volume is about normal (0.9x the 20-day average).
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $115.07 and the swing low is $94.45; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The PEG ratio is 0.41, which looks cheap relative to its expected growth.
The company reports a profit margin of 10.0% and revenue growth of +9.6%.
In its latest quarter it earned $1.52 per share, which beat the $1.36 analysts expected, with revenue +9.6% year over year.
Wall Street's average rating is 1.1 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $148.17.
Trade plan from the model
The model's long / bullish plan uses an entry near $122.09, a target of $132.53 (+8.6%) and a stop-loss at $115.42 (-5.5%).
That is a reward-to-risk ratio of about 1.6 to 1: the potential gain is larger than the potential loss.
The plan has a time limit: reassess by Nov 19, 2026 whatever the price does.
Entry$122.09
Target$132.53
Stop-loss$115.42
Reassess byNov 19, 2026
Research notes
Encompass Health’s bull case is sustained demand for inpatient rehabilitation, supported by 5.7% discharge growth, new hospitals and added beds, strong cash-flow growth, and raised 2026 revenue, EBITDA, and EPS guidance. The bear case is execution risk in new Texas facilities, staffing and payer-contract challenges, slower-than-expected ramp-ups, persistent Medicare Advantage authorization pressure, and valuation risk after a strong share-price run. The major recent catalyst was the October 28 Q3 report: revenue rose 8.9% year over year to $1.61 billion, adjusted EBITDA increased 15.5% to $346.6 million, and management lifted full-year guidance. Analysts remain broadly bullish, with a consensus price target near $148.50 versus shares around $124.
The model's one-paragraph read
Leans BUY — composite score +0.42 (BUY). Technicals: RSI 49.04, MACD bearish, price below SMA50. Fundamentals: PEG 0.41, margin 10.0%, revenue growth 9.6%. Financial results: YoY revenue +9.6%, last EPS surprise +11.8%. Smart Money Concepts: BOS bullish (trend continuation), price retesting a bullish order block, price retesting a bearish order block. FinGPT news read: positive. Internet research: Encompass Health’s **bull case** is sustained demand for inpatient rehabilitation, supported by 5.7% discharge growth, new hospitals and added beds, strong cash-flow growth, and raised 2026 revenue, EBITDA, and EPS guidance. The **bear case** is execution risk in new Texas facilities, staffing and payer-contract challenges, slower-than-expected ramp-ups, persistent Medicare Advantage authorization pressure, and valuation risk after a strong share-price run. The major recent catalyst was the October 28 Q3 report: revenue rose 8.9% year over year to $1.61 billion, adjusted EBITDA increased 15.5% to $346.6 million, and management lifted full-year guidance. Analysts remain broadly bullish, with a consensus price target near $148.50 versus shares around $124. Suggested levels: entry $122.09, target $132.53, stop-loss $115.42, exit by 2026-11-19 (21-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for EHC
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 29, 2026 | BUY | 42% | $122.09 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on EHC
Oct 29, 2026 · Encompass Health Corporation Reports Q3 2026 Results and Increases Full-Year Guidance
- Oct 29, 2026: Encompass Health Corporation Reports Q3 2026 Results and Increases Full-Year Guidance (Nasdaq)
Frequently asked questions
Is EHC a buy right now?
As of Oct 29, 2026, our automated model rates Encompass Health Corp (EHC) BUY with 42% confidence: most of the technical, fundamental, money-flow and news signals point to upside. This is a model output for education, not personal investment advice.
What is the price target for EHC?
The model's most recent plan targets $132.53 with a stop-loss at $115.42, from an entry near $122.09.
What does a BUY rating mean?
A BUY rating means most of the technical, fundamental, money-flow and news signals point to upside.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.